Aurinia Pharmaceuticals Inc. Additions Other Than Through Business Combinations Intangible Assets Other Than Goodwill
Aurinia Pharmaceuticals Inc. (AUPH) reported Additions Other Than Through Business Combinations Intangible Assets Other Than Goodwill of $17.00 thousand for the 12-month period ending 2019-12-31, per its 40-F filed 2020-03-05.
Discontinued › Notes › Intangible Assets
ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill · last filed 2020-03-05
| Period end | Additions Other Than Through Business Combinations Intangible Assets Other Than Goodwill 12 month |
|---|---|
| 2019-12-31 | $17.00K 40-F · filed 2020-03-05 |
| 2018-12-31 | $45.00K 40-F · filed 2020-03-05 |
| 2016-12-31 | $10.00K 40-F · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |